aTYR PHARMA (ATYR) EPS (Basic) Growth (3y) (2017 - 2026)
aTYR PHARMA (ATYR) EPS (Basic) Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | -38.31% |
| 10 | aTYR PHARMA | 50.11 Mn | -7.30 Mn | - | 23.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.71% |
| Mar 31, 2026 | 33.16% |
| Dec 31, 2025 | 17.29% |
| Sep 30, 2025 | 25.35% |
| Jun 30, 2025 | 19.67% |
| Mar 31, 2025 | 25.06% |
| Dec 31, 2024 | 64.74% |
| Sep 30, 2024 | 15.12% |
| Jun 30, 2024 | 21.25% |
| Mar 31, 2024 | 13.01% |
| Dec 31, 2023 | 67.49% |
| Sep 30, 2023 | 22.81% |
| Jun 30, 2023 | 20.16% |
| Mar 31, 2023 | -82.11% |
| Dec 31, 2022 | 77.00% |
| Sep 30, 2022 | 25.19% |
| Jun 30, 2022 | 38.52% |
| Mar 31, 2022 | 44.47% |
| Dec 31, 2021 | -20.44% |
| Sep 30, 2021 | 50.59% |